Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 11/2017

05.09.2017 | Original Article

Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer

verfasst von: Tobias S. Schiergens, Bernhard W. Renz, Simone Reu, Jens Neumann, Rami Al-Sayegh, Hanno Nieß, Matthias Ilmer, Stephan Kruger, Stefan Boeck, Volker Heinemann, Jens Werner, Axel Kleespies

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of this study is to investigate the prognostic value of pre-resection serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 after resection of ampullary cancer (AC) in consideration of intestinal (IT) and pancreatobiliary (PT) subtypes.

Methods

Overall survival (OS) analysis of patients undergoing curative resection of ampullary cancer.

Results

Elevated preoperative CEA (P = 0.013) and CA 19-9 levels (P = 0.030) were significant prognostic factors. Subgroup analysis, however, showed both markers having prognostic value only for the IT subgroup. Pre-resection CEA within normal range identified a subgroup of IT patients with an excellent median survival of 145 months. Compared to other AC patients, this low-risk ITCEA subpopulation was characterized by less frequent advanced pT stages (pT3/pT4, 41 vs. 62%; P = 0.047) and lymph node involvement (pN+, 30 vs. 65%; P = 0.001). OS of this subgroup was significantly better compared to other AC patients (145 vs. 25 months; HR = 3.8; P < 0.001). By multivariate survival analysis, the patient age, the PT subtype, and an elevated pre-resection serum CEA value were identified as independent prognostic variables.

Conclusions

In AC, the histomorphologic subclassification is highly relevant regarding the prognostic value of preoperative serum CEA and CA 19-9. IT-patients with normal preoperative CEA represent a favorable subgroup with excellent long-term survival.
Literatur
2.
Zurück zum Zitat Schiergens TS, Reu S, Neumann J, et al.: Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. Surgery 2015;158:151–161.CrossRefPubMed Schiergens TS, Reu S, Neumann J, et al.: Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. Surgery 2015;158:151–161.CrossRefPubMed
3.
Zurück zum Zitat Kimura W, Futakawa N, Yamagata S, et al.: Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994;85:161–166.CrossRefPubMed Kimura W, Futakawa N, Yamagata S, et al.: Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994;85:161–166.CrossRefPubMed
4.
Zurück zum Zitat Chang DK, Jamieson NB, Johns AL, et al.: Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 2013;31:1348–1356.CrossRefPubMed Chang DK, Jamieson NB, Johns AL, et al.: Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 2013;31:1348–1356.CrossRefPubMed
5.
Zurück zum Zitat Morini S, Perrone G, Borzomati D, et al.: Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival. Pancreas 2013;42:60–66.CrossRefPubMed Morini S, Perrone G, Borzomati D, et al.: Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival. Pancreas 2013;42:60–66.CrossRefPubMed
6.
Zurück zum Zitat Westgaard A, Tafjord S, Farstad IN, et al.: Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008;8:170.CrossRefPubMedPubMedCentral Westgaard A, Tafjord S, Farstad IN, et al.: Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008;8:170.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Distler M, Pilarsky E, Kersting S, et al.: Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas—a retrospective tumor marker prognostic study. Int J Surg 2013;11:1067–1072.CrossRefPubMed Distler M, Pilarsky E, Kersting S, et al.: Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas—a retrospective tumor marker prognostic study. Int J Surg 2013;11:1067–1072.CrossRefPubMed
8.
Zurück zum Zitat Albores-Saavedra J, Schwartz AM, Batich K, et al.: Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 2009;100:598–605.CrossRefPubMed Albores-Saavedra J, Schwartz AM, Batich K, et al.: Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 2009;100:598–605.CrossRefPubMed
9.
Zurück zum Zitat Westgaard A, Pomianowska E, Clausen OP, et al.: Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies? Ann Surg Oncol 2013;20:430–439.CrossRefPubMed Westgaard A, Pomianowska E, Clausen OP, et al.: Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies? Ann Surg Oncol 2013;20:430–439.CrossRefPubMed
10.
Zurück zum Zitat Albores-Saavedra J: Invasive adenocarcinoma of the ampullary region. In: Bosman FT, et al. (ed): WHO Classification of Tumours of the Digestive System, IARC 2010, Lyon. Albores-Saavedra J: Invasive adenocarcinoma of the ampullary region. In: Bosman FT, et al. (ed): WHO Classification of Tumours of the Digestive System, IARC 2010, Lyon.
11.
Zurück zum Zitat Ballehaninna UK, Chamberlain RS: Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol 2013;34:3279–3292.CrossRefPubMed Ballehaninna UK, Chamberlain RS: Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumour Biol 2013;34:3279–3292.CrossRefPubMed
12.
Zurück zum Zitat Boeck S, Stieber P, Holdenrieder S, et al.: Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255–264.CrossRefPubMed Boeck S, Stieber P, Holdenrieder S, et al.: Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255–264.CrossRefPubMed
13.
Zurück zum Zitat Fry LC, Monkemuller K, Malfertheiner P: Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 2008;393:883–890.CrossRefPubMed Fry LC, Monkemuller K, Malfertheiner P: Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 2008;393:883–890.CrossRefPubMed
14.
Zurück zum Zitat Bergquist JR, Puig CA, Shubert CR, et al.: Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. J Am Coll Surg 2016;223:52–65.CrossRefPubMed Bergquist JR, Puig CA, Shubert CR, et al.: Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. J Am Coll Surg 2016;223:52–65.CrossRefPubMed
15.
Zurück zum Zitat Duffy MJ, Sturgeon C, Lamerz R, et al.: Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441–447.CrossRefPubMed Duffy MJ, Sturgeon C, Lamerz R, et al.: Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441–447.CrossRefPubMed
16.
Zurück zum Zitat Tempero MA, Uchida E, Takasaki H, et al.: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501–5503.PubMed Tempero MA, Uchida E, Takasaki H, et al.: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987;47:5501–5503.PubMed
17.
Zurück zum Zitat Williams JL, Kadera BE, Nguyen AH, et al.: CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. J Gastrointest Surg 2016;20:1331–1342.CrossRefPubMedPubMedCentral Williams JL, Kadera BE, Nguyen AH, et al.: CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. J Gastrointest Surg 2016;20:1331–1342.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Schlieman MG, Ho HS, Bold RJ: Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;38:951–955.CrossRef Schlieman MG, Ho HS, Bold RJ: Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;38:951–955.CrossRef
19.
Zurück zum Zitat Katsanos KH, Kitsanou M, Christodoulou DK, et al.: High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur J Intern Med 2002;13:132–135.CrossRefPubMed Katsanos KH, Kitsanou M, Christodoulou DK, et al.: High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur J Intern Med 2002;13:132–135.CrossRefPubMed
20.
Zurück zum Zitat Lurie BB, Loewenstein MS, Zamcheck N: Elevated carcinoembryonic antigen levels and biliary tract obstruction. JAMA 1975;233:326–330.CrossRefPubMed Lurie BB, Loewenstein MS, Zamcheck N: Elevated carcinoembryonic antigen levels and biliary tract obstruction. JAMA 1975;233:326–330.CrossRefPubMed
21.
Zurück zum Zitat Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350–355.PubMed Steinberg W: The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350–355.PubMed
23.
Zurück zum Zitat Kim RD, Kundhal PS, McGilvray ID, et al.: Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg 2006;202:112–119.CrossRefPubMed Kim RD, Kundhal PS, McGilvray ID, et al.: Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg 2006;202:112–119.CrossRefPubMed
24.
Zurück zum Zitat Kim WS, Choi DW, Choi SH, et al.: Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol 2012;105:266–272.CrossRefPubMed Kim WS, Choi DW, Choi SH, et al.: Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol 2012;105:266–272.CrossRefPubMed
25.
Zurück zum Zitat Colussi O, Voron T, Pozet A, et al.: Prognostic score for recurrence after Whipple’s pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort. Eur J Surg Oncol 2015;41:520–526.CrossRefPubMed Colussi O, Voron T, Pozet A, et al.: Prognostic score for recurrence after Whipple’s pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort. Eur J Surg Oncol 2015;41:520–526.CrossRefPubMed
26.
27.
Zurück zum Zitat Barauskas G, Urbonas K, Smailyte G, et al.: Preoperative Endoscopic Biliary Drainage May Negatively Impact Survival Following Pancreatoduodenectomy for Ampullary Cancer. Dig Surg 2016;33:462–469.CrossRefPubMed Barauskas G, Urbonas K, Smailyte G, et al.: Preoperative Endoscopic Biliary Drainage May Negatively Impact Survival Following Pancreatoduodenectomy for Ampullary Cancer. Dig Surg 2016;33:462–469.CrossRefPubMed
28.
Zurück zum Zitat Zhao X, Dong J, Huang X, et al.: Prognostic factors for survival of patients with ampullary carcinoma after local resection. ANZ J Surg 2015;85:567–571.CrossRefPubMed Zhao X, Dong J, Huang X, et al.: Prognostic factors for survival of patients with ampullary carcinoma after local resection. ANZ J Surg 2015;85:567–571.CrossRefPubMed
29.
Zurück zum Zitat Qiao QL, Zhao YG, Ye ML, et al.: Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007;31:137–143.CrossRefPubMed Qiao QL, Zhao YG, Ye ML, et al.: Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007;31:137–143.CrossRefPubMed
30.
Zurück zum Zitat Shinkawa H, Takemura S, Kiyota S, et al.: Long-term outcome of surgical treatment for ampullary carcinoma. Hepatogastroenterology 2012;59:1010–1012.PubMed Shinkawa H, Takemura S, Kiyota S, et al.: Long-term outcome of surgical treatment for ampullary carcinoma. Hepatogastroenterology 2012;59:1010–1012.PubMed
31.
Zurück zum Zitat Schueneman A, Goggins M, Ensor J, et al.: Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer 2015;113:64–68.CrossRefPubMedPubMedCentral Schueneman A, Goggins M, Ensor J, et al.: Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer 2015;113:64–68.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Smith RA, Ghaneh P, Sutton R, et al.: Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008;12:1422–1428.CrossRefPubMed Smith RA, Ghaneh P, Sutton R, et al.: Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008;12:1422–1428.CrossRefPubMed
33.
34.
Zurück zum Zitat Mery CM, Duarte-Rojo A, Paz-Pineda F, et al.: Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer? Rev Invest Clin 2001;53:511–517.PubMed Mery CM, Duarte-Rojo A, Paz-Pineda F, et al.: Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer? Rev Invest Clin 2001;53:511–517.PubMed
35.
Zurück zum Zitat Marrelli D, Caruso S, Pedrazzani C, et al.: CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009:198:333–339.CrossRefPubMed Marrelli D, Caruso S, Pedrazzani C, et al.: CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009:198:333–339.CrossRefPubMed
36.
Zurück zum Zitat Mani S, Kugler JW, Knost JA, et al.: Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs 1998;16:275–278.CrossRefPubMed Mani S, Kugler JW, Knost JA, et al.: Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs 1998;16:275–278.CrossRefPubMed
37.
Zurück zum Zitat Ballehaninna UK, Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012;3:105–119.PubMedPubMedCentral Ballehaninna UK, Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012;3:105–119.PubMedPubMedCentral
Metadaten
Titel
Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer
verfasst von
Tobias S. Schiergens
Bernhard W. Renz
Simone Reu
Jens Neumann
Rami Al-Sayegh
Hanno Nieß
Matthias Ilmer
Stephan Kruger
Stefan Boeck
Volker Heinemann
Jens Werner
Axel Kleespies
Publikationsdatum
05.09.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 11/2017
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3489-8

Weitere Artikel der Ausgabe 11/2017

Journal of Gastrointestinal Surgery 11/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.